Select Page

South Delhi Pharma, New Delhi, India

XOSPATA ® (gilteritinib) tablets, for oral use.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

XOSPATA is a prescription medicine.XOSPATA is used to treat acute myeloid leukaemia (AML).
INDICATIONS AND USAGE
XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
DOSAGE FORMS & STRENGTHS
120 mg orally once daily.
Manufactured By: Astellas Pharma US, Inc
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “XOSPATA ® (gilteritinib) tablets” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

14 + 2 =

Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug.[6] It acts as an inhibitor of AXL receptor tyrosine kinase, hence it is a tyrosine kinase inhibitor.

It was developed by Astellas Pharma.

In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML).[8]

In November 2018, the FDA approved gilteritinib for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Gilteritinib was granted orphan drug status by the U.S. FDA, the European Commission (EC) and the Japan Ministry of Health, Labor and Welfare, for some AML patients.

Gilteritinib was approved for medical use in Australia in March 2020.

2 reviews for XOSPATA ® (gilteritinib) tablets, for oral use.

  1. zovrelioptor

    Good write-up, I am normal visitor of one?¦s site, maintain up the excellent operate, and It is going to be a regular visitor for a lengthy time.

    http://www.zovrelioptor.com/

  2. zortilonrel

    Great wordpress blog here.. It’s hard to find quality writing like yours these days. I really appreciate people like you! take care

    http://www.zortilonrel.com/

Add a review

Your email address will not be published.